Effect of Hyperandrogenism on IVF Success Rates in PCOS Patients

Status: Recruiting
Location: See location...
Intervention Type: Other
Study Type: Observational
SUMMARY

Ovulatory dysfunction affects 18 to 25% of infertile women, the most common identifiable condition is polycystic ovarian syndrome (PCOS). The most frequent symptoms of PCOS are oligo-anovulation, hyperandrogenism and polycystic ovary appearance. Hyperandrogenism is the main contributor that affects oocyte and embryo quality and decreases the success rates in PCOS patients undergoing IVF treatments. The aim of this study is to determine the effect of hyperandrogenism as an independent factor on IVF success rates and oocyte/embryo quality in PCOS patients undergoing IVF.

Eligibility
Participation Requirements
Sex: Female
Minimum Age: 18
Maximum Age: 39
View:

• Women between ages of 18 - 39 inclusively

• ≥15 oocytes collected on the day of oocyte retrieval and/or anti-mullerian hormone (AMH) ≥ 4.0 ng/ml in the participant's medical chart in the last 24 months

Locations
Other Locations
Canada
Clinique Ovo
RECRUITING
Montreal
Contact Information
Primary
Nelly Delouya, RN
n.delouya@cliniqueovo.com
15147982000
Backup
Marion Vivien, PhD
m.vivien@cliniqueovo.com
5147982000
Time Frame
Start Date: 2022-01-21
Estimated Completion Date: 2025-12-30
Participants
Target number of participants: 188
Treatments
PCOS patients with clinical or biochemical hyperandrogenism
Clinical hyperandrogenism consists of patients with one of the following conditions: Acne, Hirsutism (using modified Ferriman-Gallwey (FG) score) or Androgenic alopecia Biochemical hyperandrogenism consists of elevated serum level of at least one of the following hormones: Total testosterone, free testosterone, DHEAS, androstenedione using the cut-offs adopted by the laboratory.
PCOS patients with no clinical or biochemical hyperandrogenism
In this cohort, women have not be affected by either clinical of biochemical hyperandrogenism. The PCOS diagnosis will be based on oligo-anovulation and on polycystic ovaries during an ultrasound
Sponsors
Leads: Clinique Ovo

This content was sourced from clinicaltrials.gov